Detalhe da pesquisa
1.
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(7): 916-929, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29908991